Industry Newsclinical trialsmuscular dystrophyedgewise therapeuticscardiac therapeutics
Edgewise Therapeutics Outlines 2026 Milestones, Trial Timetable
|
4.9
Edgewise Therapeutics (NASDAQ:EWTX) provided a corporate update on January 13, 2026, after shares rose 57% over the prior three months. The company said it expects top-line Sevasemten results by Q4 2026 as a potential first approved therapy for Becker disease and anticipates Phase 2 EDG-7500 results in H1 2026 for HCM. Analysts hold a consensus Strong Buy and $38.14 target.
Scoring Rationale
Provides timely company milestones and analyst context but limited novelty and promotional, shallow coverage.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
